Autolus Therapeutics (NASDAQ:AUTL) Insider Cintia Piccina Sells 6,713 Shares of Stock

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) insider Cintia Piccina sold 6,713 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $2.34, for a total transaction of $15,708.42. Following the sale, the insider owned 13,287 shares in the company, valued at $31,091.58. This trade represents a 33.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Autolus Therapeutics Price Performance

Shares of NASDAQ AUTL opened at $2.29 on Friday. The firm has a market cap of $609.51 million, a PE ratio of -2.16 and a beta of 2.10. The company has a fifty day moving average price of $1.87 and a 200 day moving average price of $1.66. Autolus Therapeutics PLC Sponsored ADR has a 1-year low of $1.17 and a 1-year high of $2.58. The company has a current ratio of 4.89, a quick ratio of 4.40 and a debt-to-equity ratio of 1.04.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Tuesday, August 11th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.06. The firm had revenue of $45.69 million for the quarter, compared to analysts’ expectations of $38.56 million. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%. Research analysts predict that Autolus Therapeutics PLC Sponsored ADR will post -0.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on AUTL. Wall Street Zen raised shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, August 3rd. Finally, Weiss Ratings upgraded shares of Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $10.00.

Institutional Investors Weigh In On Autolus Therapeutics

Large investors have recently made changes to their positions in the stock. Mak Capital One LLC increased its holdings in Autolus Therapeutics by 15.3% during the fourth quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock worth $59,711,000 after buying an additional 3,987,727 shares during the last quarter. Armistice Capital LLC lifted its stake in Autolus Therapeutics by 12.2% in the fourth quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock valued at $34,825,000 after acquiring an additional 1,900,000 shares during the last quarter. Syncona Portfolio Ltd acquired a new stake in Autolus Therapeutics in the second quarter valued at $26,625,152. Schroder Investment Management Group grew its position in shares of Autolus Therapeutics by 12.5% in the 4th quarter. Schroder Investment Management Group now owns 9,489,345 shares of the company’s stock valued at $18,694,000 after acquiring an additional 1,056,092 shares during the period. Finally, Bank of America Corp DE grew its position in shares of Autolus Therapeutics by 108.1% in the 3rd quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock valued at $3,308,000 after acquiring an additional 1,054,458 shares during the period. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.